Last updated: February 23, 2026
What is the Drug Detailing?
NDC 00536-1101 corresponds to Lisdexamfetamine Dimesylate, marketed primarily under the brand name Vyvanse. It is a central nervous system stimulant indicated for Attention Deficit Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED).
Market Size and Growth Drivers
Global ADHD market:
- Valued at approximately $15 billion in 2022.
- Compound annual growth rate (CAGR) projected at 5.2% from 2022-2030 [1].
Key drivers:
- Rising diagnosis rates of ADHD in children and adults.
- Increased off-label use for cognitive enhancement.
- Expansion into new markets, especially in Asia-Pacific and Latin America.
Vyvanse's market share:
- Holds roughly 65% of the stimulant segment in the U.S. ADHD drug market.
- Revenue reached approximately $4.2 billion in 2022 [2].
Competitive Landscape
Major competitors include:
- Adderall (amphetamine and dextroamphetamine): Generic versions dominate U.S. sales, with a market share of around 45%.
- Concerta (methylphenidate)): Accounts for approximately 20% of the market.
- Other branded options: Daytrana, Focalin, and generic formulations.
The market is constrained by patent expirations:
- Vyvanse's initial patent expired in 2023.
- Several generics are now available, leading to significant price erosion.
Pricing Dynamics
Brand-name Vyvanse:
- Average wholesale price (AWP): Approximately $290 per 30-count, 30 mg capsules [3].
Generics:
- Priced at approximately $150–$180 per 30-count, largely displacing branded versions.
Price erosion post-patent expiry:
- Price for branded Vyvanse decreased by roughly 30% within the first year after patent expiry.
- Generics introduced across multiple strengths, further driving down prices.
Pricing Projections (2023-2027)
| Year |
Estimated Brand Price (30 mg, 30-count) |
Estimated Generic Price (30 mg, 30-count) |
| 2023 |
$280–$290 |
$150–$180 |
| 2024 |
$260–$275 |
$130–$160 |
| 2025 |
$240–$260 |
$110–$140 |
| 2026 |
$220–$240 |
$100–$130 |
| 2027 |
$210–$230 |
$90–$120 |
Market dynamics suggest sustained price decline for both branded and generic forms due to increased competition and payor pressure.
Revenue Outlook
- 2023: Revenue from Vyvanse expected to decline by 25%–30% from 2022 levels.
- Long-term: Competition will likely stabilize revenue at 50-60% of peak sales, projected around $2–$2.5 billion annually.
Growth potential hinges on novel formulations and expanded indications, which currently face regulatory and patent-related barriers.
Regulatory and Patent Status
- Original patent protection expired in 2023.
- Patent challenges threaten any remaining exclusivity.
- No recent regulatory approvals for new formulations or indications.
Key Risks and Opportunities
Risks:
- Higher generic penetration reduces brand revenues.
- Price pressure from payors and pharmacy benefit managers.
Opportunities:
- Potential pipeline expansion into adult ADHD or additional psychiatric conditions.
- Differentiation through formulation improvements (e.g., abuse-deterrent versions).
Key Takeaways
- The market for NDC 00536-1101 has experienced rapid erosion post-patent expiry due to generics.
- Despite declining prices, demand remains stable owing to ADHD prevalence and approved indications.
- Future revenue will decrease unless new formulations or indications emerge.
- Competition is fierce, with generic pricing dictating the market for the foreseeable future.
FAQs
1. Why did Vyvanse's patent expire in 2023?
The original patent covering Vyvanse's formulation and method of use expired, allowing generic manufacturers to produce competing versions.
2. How much have generic versions impacted Vyvanse sales?
Generics are estimated to account for around 70% of the stimulant ADHD market share post-2023, leading to significant revenue declines for the brand.
3. Are there ongoing patent litigations or exclusivity rights?
No significant patent protections remain; the primary patents expired. Some secondary patents may exist but lack market significance.
4. What is the outlook for prices of Vyvanse in the next five years?
Brand prices will likely stabilize around $200–$220 per 30-count 30 mg capsule; generics may fall below $100, further pressuring overall market prices.
5. Can new indications or formulations revive Vyvanse’s market?
Potential exists if regulatory approval for novel formulations or additional psychiatric indications occurs, but current pipeline development is limited.
References
- IQVIA. (2022). Global ADHD market report.
- EvaluatePharma. (2022). Vyvanse sales data.
- Red Book. (2023). Wholesale drug prices.
- U.S. Food and Drug Administration. (2023). Patent status and exclusivity data.
- U.S. Patent and Trademark Office. (2023). Patent expirations and challenges.
